Aenitis, a Paris, France-based acoustic-based cell manipulation company, raised a strategic founding of undisclosed amount.
Backers included European Innovation Council Fund advised by the European Investment Bank, Quadrivium I fund managed by Seventure Partners, Mifani Invest, Stamos, Weaving Invest, a few business angels and the company founders. In conjunction with the funding, Eric Garnier, former Vice President and General Manager of Pall Medical, joined the Strategic Board as Independent Chairman and will be instrumental in accelerating revenue and profit growth and establishing new partnerships. In addition, Michel Spagnol will represent Mifani Invest and bring his expertise and network, notably as former Chairman and CEO of Novasep, which will help structure the Company.
The company intends to use the funds to drive its technology towards commercial launch and global expansion.
Led by CEO Emmanuel Vincent, Aenitis designs, develops, and markets sole-in-class acoustofluidic technology that makes cell and gene therapy manufacturing safer and less expensive. By controlling levitated cells with sound waves, its systems handle cells in full sterile conditions, increasing productivity while preserving the native state of cells at every step of the engineering process.
Mitis™, the flagship product of its Acoustofluidic Technology, is already used across various applications, from research to clinical and industrial scales, including cell sorting, isolation, concentration, and washing.
Since its inception, Aenitis has raised a total of €14.5M
FinSMEs
14/10/2024